Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess

What Was Tested

This randomized controlled trial paper looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

Six normal subjects (four females and two males) matched for sex and age with the patients and not undergoing any therapy served as controls.

Who Took Part

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, single-blind and crossover study.

Random assignment meant chance, not the researchers, decided who got Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and who got the comparison, which limits bias.

Only one side, usually the participants, was kept unaware of whether Exogenous HGH, sermorelin & older GHRPs (why they're passed over) was given.

Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.

What Was Measured

The subject headings attached to it are Drug Synergism, Glucocorticoids, Growth Hormone, Growth Hormone-Releasing Hormone, Growth Substances, Oligopeptides and Stimulation, Chemical.

What This Means in Plain Language

The paper is a randomized, single-blind and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRH (Growth Hormone-Releasing Hormone).

The publication is from 1995 (The Journal of endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.